NCT01470131 - A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 4, 2017

Study Completion Date

February 1, 2017

Conditions

Multiple Myeloma

Interventions

DRUG

Masitinib

Masitinib 6 mg/kg/day

DRUG

Placebo

Matching placebo

DRUG

Bortezomib

Standard therapy (cycles of bortezomib)

DRUG

Dexamethasone

Standard therapy (cycles of dexamethasone)

Trial Locations (13)

Center for Cancer and Blood Disorders, Bethesda

Southeastern Medical Oncology Center, Goldsboro

Carolinas Medical Center, Charlotte

Froedtert & Medical College of Wisconsin-CLCC, Milwaukee

Medical and Surgical Specialists, Galesburg

CHU Estaing, Clermont-Ferrand

Centre Hospitalier Sud Francilien, Corbeil-Essonnes

CH Le Mans, Le Mans

Hôpital Universitaire Dupuytren, Limoges

Hôpital Ambroise Paré, Marseille

Hôpital de l'Hôtel Dieu, Nantes

Hôpital Saint Louis, Paris

Centre Hospitalier Saint Jean, Perpignan